Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Not currently pregnant or lactating and is highly unlikely to conceive~* Body Mass Index (BMI) between 20-30 kilograms per meter squared (kg/m2) inclusive.~* Body weight, as reported by patient, stable (±2 kg) for \>6 weeks~* Plasma low density lipoprotein cholesterol (LDL-C) between 130 and 180 milligrams per deciliter (mg/dL) inclusive. Note: One retest allowed.~* Triglyceride (TG) concentrations ≤150 mg/dL. Note: One retest allowed.~* Fasting blood glucose \<110 mg/dL and hemoglobin A1c (HbA1C) ≤ 6 percent at Visit 1. Note: One retest allowed.~* Liver transaminases (ALT, AST) ≤1.5 x upper limit of normal (ULN) and no active liver disease. Note: One retest allowed.~* Creatine Phosphokinase (CPK) ≤2x ULN. Note: One retest allowed.~* Willingness to maintain a stable diet for the duration of the study.~* Can understand and comply with study procedures and signs a written informed consent.~* Patient is ≥80 precent compliant with dosing during Placebo Run-In Period or, in the opinion of the investigator, is able to maintain ≥80 percent therapy compliance during the active treatment period of the study.~Exclusion Criteria:~* Lipid-lowering therapy and replacement of this therapy with study medication is considered inappropriate by the investigator.~* Consumes an average of more than 2 alcoholic drinks per day.~* Smokes.~* Currently engages in a vigorous exercise regimen or intensive exercise bouts \>4x per month.~* Treated with any other investigational drug within 30 days of Visit 1.~* Hypersensitivity or intolerance to ezetimibe or any component of this medication.~* Any condition or situation which poses a risk to the patient or interfere with participation in the study.~* Congestive heart failure.~* Uncontrolled cardiac arrhythmias.~* History of myocardial infarction, stroke, or any other clinical manifestation of coronary, cerebral, or peripheral vascular disease.~* Uncontrolled hypertension~* Impaired renal function, nephrotic syndrome or other clinically significant renal disease at Visit 1.~* Active or chronic hepatobiliary or hepatic disease.~* History of irritable bowel syndrome, ileal bypass, gastric bypass or any gastrointestinal disorder/condition associated with malabsorption.~* Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins.~* Type I or Type II diabetes mellitus.~* Disorders of the hematologic, digestive, or central nervous systems including cerebrovascular disease and degenerative disease that would limit study evaluation or participation.~* Human Immunodeficiency Virus (HIV) positive.~* History of cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas).~* History of uncontrolled psychiatric illness or drug/alcohol abuse within the past 5 years. Individuals with psychiatric illness adequately controlled and stable on pharmacotherapy may be enrolled at the discretion of the investigator.~* Lipid-lowering agents taken within 6 weeks and fibrates taken within 8 weeks prior to visit 3.~* Cardiovascular medications are acceptable provided the patient has been on a stable regimen for at least 6 weeks prior to Visit 3 and indicates a willingness to continue the stable regimen for the duration of the study.~* Supplementation with antioxidants beyond a standard multivitamin for the duration of the study.~* Psyllium, other fiber-based laxatives, and/or over the counter (OTC) therapies known to affect serum lipid levels taken within 6 weeks of Visit 3.~* Female patients receiving hormone replacement therapy, any estrogen antagonist/agonist or hormonal contraceptives.~* Treatment with cyclosporine except for ophthalmic indication~* Anti-obesity medications such as orlistat or sibutramine taken within 3 months prior to Visit 1.~* Therapeutic doses of systemic corticosteroids except inhaled steroid therapy (for example, Pulmicort®) maintained on a stable dosing regimen for at least 6 weeks prior to randomization (Visit 3) and throughout the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Sugar Pill (Type: PLACEBO_COMPARATOR): Placebo medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
- ezetimibe (Type: EXPERIMENTAL): 10 mg medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).